{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:54:33Z","timestamp":1791644073117,"version":"4.3.4"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"publisher","award":["R096769PRE3008"],"award-info":[{"award-number":["R096769PRE3008"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ClinicalTrials.gov","award":["NCT01063855"],"award-info":[{"award-number":["NCT01063855"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Men with comorbid erectile dysfunction (ED) and premature ejaculation (PE) may be concomitantly prescribed a phosphodiesterase type 5 (PDE5) inhibitor and dapoxetine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Evaluate efficacy and safety of dapoxetine 30mg and 60mg on demand (prn) in men with PE and ED who were being treated with PDE5 inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This randomized, double-blind, placebo-controlled, flexible-dose, multicenter study enrolled men \u226518 years who met diagnostic criteria for PE including intravaginal ejaculatory latency time (IELT) of \u22642 minutes in \u226575% of sexual intercourse episodes; were on stable regimen of a PDE5 inhibitor; and had International Index of Erectile Function-erectile function domain score \u226521. Subjects received placebo, dapoxetine 30mg, or dapoxetine 60mg prn (1\u20133 hours before intercourse) for 12 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measure<\/jats:title>\n                    <jats:p>Stopwatch-measured average IELT, Clinical Global Impression of Change (CGIC) in PE, Premature Ejaculation Profile (PEP), and treatment-emergent adverse events (TEAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 495 subjects randomized, 429 completed the study. Arithmetic mean average IELT significantly increased with dapoxetine vs. placebo at end point (5.2 vs. 3.4 minutes) and weeks 4, 8, and 12 (P \u22640.002 for all). Men who described their PE at least \u201cbetter\u201d using the CGIC were significantly greater with dapoxetine vs. placebo at end point (56.5% vs. 35.4%) and weeks 4, 8, and 12 (P \u22640.001 for all). Significantly better outcomes were also reported with dapoxetine vs. placebo on PEP measures. Incidence of TEAEs was 20.0% and 29.6% in placebo- and dapoxetine-treated subjects, respectively (P =0.0135). TEAEs led to discontinuation in 1.6% of subjects in both groups. Most frequent TEAEs were known adverse drug reactions of dapoxetine treatment including nausea (9.2%), headache (4.4%), diarrhea (3.6%), dizziness (2.4%), and dizziness postural (2.4%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In men with PE and comorbid ED on a stable regimen of PDE5 inhibitor, dapoxetine provided meaningful treatment benefit and was generally well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jsm.12236","type":"journal-article","created":{"date-parts":[[2013,7,11]],"date-time":"2013-07-11T11:32:41Z","timestamp":1373542361000},"page":"2312-2325","source":"Crossref","is-referenced-by-count":64,"title":["Efficacy and Safety of Dapoxetine in Men with Premature Ejaculation and Concomitant Erectile Dysfunction Treated with a Phosphodiesterase Type 5 Inhibitor: Randomized, Placebo-Controlled, Phase III Study"],"prefix":"10.1093","volume":"10","author":[{"given":"Chris G.","family":"McMahon","sequence":"first","affiliation":[{"name":"Australian Centre for Sexual Health , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Giuliano","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation \u00a0 \u00a0 , Garches , France"},{"name":"Neuro-Urology-Andrology, Raymond Poincare' Hospital \u00a0 \u00a0 , Garches , France"},{"name":"Garches, Versailles Saint Quentin en Yvelines University \u00a0 \u00a0 , Garches , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Dean","sequence":"additional","affiliation":[{"name":"The London Clinic , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne J.G.","family":"Hellstrom","sequence":"additional","affiliation":[{"name":"Department of Urology \u00a0 , New Orleans, LA , USA"},{"name":"Tulane University School of Medicine \u00a0 , New Orleans, LA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Bull","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical Research & Development, LLC , Raritan, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fisseha","family":"Tesfaye","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical Research & Development, LLC , Raritan, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Om","family":"Sharma","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical Research & Development, LLC , Raritan, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Rivas","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical Research & Development, LLC , Raritan, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Aquilina","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical Research & Development, LLC , Raritan, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,9,1]]},"reference":[{"key":"2024032601023743500_bb0010","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1111\/j.1743-6109.2010.01975.x","article-title":"International Society for Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation","volume":"7","author":"Althof","year":"2010","journal-title":"J Sex Med"},{"key":"2024032601023743500_bb0015","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.eururo.2010.02.020","article-title":"Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation","volume":"57","author":"Hatzimouratidis","year":"2010","journal-title":"Eur Urol"},{"key":"2024032601023743500_bb0020","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1743-6109.2008.00901.x","article-title":"An evidence-based definition of lifelong premature ejaculation: Report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation","volume":"5","author":"McMahon","year":"2008","journal-title":"J Sex Med"},{"issue":"suppl 4","key":"2024032601023743500_bb0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1743-6109.2006.00307.x","article-title":"Diagnosing premature ejaculation: A review","volume":"3","author":"Shabsigh","year":"2006","journal-title":"J Sex Med"},{"key":"2024032601023743500_bb0030","article-title":"Diagnostic and statistical manual of mental disorders","year":"2000"},{"key":"2024032601023743500_bb0035","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.eururo.2009.01.025","article-title":"Dapoxetine for the treatment of premature ejaculation: Results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries","volume":"55","author":"Buvat","year":"2009","journal-title":"Eur Urol"},{"key":"2024032601023743500_bb0040","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1464-410X.2008.08165.x","article-title":"Treatment benefit of dapoxetine for premature ejaculation: Results from a placebo-controlled phase III trial","volume":"103","author":"Kaufman","year":"2009","journal-title":"BJU Int"},{"key":"2024032601023743500_bb0045","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1743-6109.2009.01560.x","article-title":"Treatment of premature ejaculation in the Asia-Pacific region: Results from a phase III double-blind, parallel-group study of dapoxetine","volume":"7","author":"McMahon","year":"2010","journal-title":"J Sex Med"},{"key":"2024032601023743500_bb0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(06)69373-2","article-title":"Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: An integrated analysis of two double-blind, randomised controlled trials","volume":"368","author":"Pryor","year":"2006","journal-title":"Lancet"},{"key":"2024032601023743500_bb0055","article-title":"Priligy (dapoxetine) [prescribing information]","author":"Janssen Cilag","year":"2008"},{"key":"2024032601023743500_bb0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"Impotence. NIH consensus development panel on impotence","volume":"270","author":"NIH Consensus Conference","year":"1993","journal-title":"JAMA"},{"key":"2024032601023743500_bb0065","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1111\/j.1743-6109.2010.02062.x","article-title":"Summary of the recommendations on sexual dysfunctions in men","volume":"7","author":"Montorsi","year":"2010","journal-title":"J Sex Med"},{"key":"2024032601023743500_bb0070","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1743-6109.04041.x","article-title":"Prevalence of erectile dysfunction among young adults: Results of a large-scale survey","volume":"1","author":"Heruti","year":"2004","journal-title":"J Sex Med"},{"issue":"suppl 4","key":"2024032601023743500_bb0075","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/sj.ijir.3900567","article-title":"The worldwide prevalence and epidemiology of erectile dysfunction","volume":"12","author":"McKinlay","year":"2000","journal-title":"Int J Impot Res"},{"key":"2024032601023743500_bb0080","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/aja.2010.131","article-title":"Prevalence and medical management of erectile dysfunction in Asia","volume":"13","author":"Park","year":"2010","journal-title":"Asian J Androl"},{"key":"2024032601023743500_bb0085","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/sj.ijir.3900905","article-title":"Prevalence of erectile dysfunction: A systematic review of population-based studies","volume":"14","author":"Prins","year":"2002","journal-title":"Int J Impot Res"},{"key":"2024032601023743500_bb0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amjmed.2006.06.010","article-title":"Prevalence and risk factors for erectile dysfunction in the US","volume":"120","author":"Selvin","year":"2007","journal-title":"Am J Med"},{"key":"2024032601023743500_bb0095","article-title":"Viagra (sildenafil citrate) [package insert]","author":"Pfizer, Inc.","year":"2005"},{"key":"2024032601023743500_bb0100","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1097\/01.ju.0000067820.86347.95","article-title":"Erectile dysfunction in the elderly: Epidemiology, etiology and approaches to treatment","volume":"169","author":"Seftel","year":"2003","journal-title":"J Urol"},{"key":"2024032601023743500_bb0105","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.ijir.3900914","article-title":"Sexual disabilities are not singularities","volume":"14","author":"Fugl-Meyer","year":"2002","journal-title":"Int J Impot Res"},{"key":"2024032601023743500_bb0110","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00345-006-0088-9","article-title":"Sexual behaviour, sexual dysfunctions and related help seeking patterns in middle-aged and elderly Europeans: The global study of sexual attitudes and behaviors","volume":"24","author":"Nicolosi","year":"2006","journal-title":"World J Urol"},{"key":"2024032601023743500_bb0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.ijir.3901250","article-title":"Sexual problems among women and men aged 40\u201380 y: Prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors","volume":"17","author":"Laumann","year":"2005","journal-title":"Int J Impot Res"},{"key":"2024032601023743500_bb0120","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.ju.0000132159.61156.ea","article-title":"AUA guideline on the pharmacologic management of premature ejaculation","volume":"172","author":"Montague","year":"2004","journal-title":"J Urol"},{"key":"2024032601023743500_bb0125","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1111\/j.1743-6109.2011.02628.x","article-title":"Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? A systematic review and meta-analysis","volume":"9","author":"Asimakopoulos","year":"2012","journal-title":"J Sex Med"},{"key":"2024032601023743500_bb0130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1464-410X.2006.06290.x","article-title":"Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: A systematic review","volume":"98","author":"McMahon","year":"2006","journal-title":"BJU Int"},{"key":"2024032601023743500_bb0135","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0090-4295(02)02075-7","article-title":"Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation","volume":"61","author":"Chen","year":"2003","journal-title":"Urology"},{"key":"2024032601023743500_bb0140","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/sj.ijir.3901420","article-title":"Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors","volume":"18","author":"Dresser","year":"2006","journal-title":"Int J Impot Res"},{"key":"2024032601023743500_bb0145","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1743-6109.2007.00464.x","article-title":"Interrelationships among measures of premature ejaculation: The central role of perceived control","volume":"4","author":"Patrick","year":"2007","journal-title":"J Sex Med"},{"key":"2024032601023743500_bb0150","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1464-410X.2008.07845.x","article-title":"Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: Results from phase III trials with dapoxetine","volume":"102","author":"Shabsigh","year":"2008","journal-title":"BJU Int"},{"key":"2024032601023743500_bb0155","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1743-6109.2007.00696.x","article-title":"Geometric mean IELT and premature ejaculation: Appropriate statistics to avoid overestimation of treatment efficacy","volume":"5","author":"Waldinger","year":"2008","journal-title":"J Sex Med"},{"key":"2024032601023743500_bb0160","first-page":"715","article-title":"Escitalopram related erectile dysfunction and spontaneous ejaculation during micturition","volume":"59","author":"Belli","year":"2010","journal-title":"West Indian Med J"},{"key":"2024032601023743500_bb0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/00926239808414663","article-title":"Sexual dysfunction induced by serotonin reuptake antidepressants","volume":"24","author":"Labbate","year":"1998","journal-title":"J Sex Marital Ther"},{"key":"2024032601023743500_bb0170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4306\/pi.2010.7.1.55","article-title":"Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting","volume":"7","author":"Lee","year":"2010","journal-title":"Psychiatry Investig"},{"key":"2024032601023743500_bb0175","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/00926239708403923","article-title":"SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients","volume":"23","author":"Montejo-Gonzalez","year":"1997","journal-title":"J Sex Marital Ther"},{"key":"2024032601023743500_bb0180","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1198\/016214508000000986","article-title":"On adaptive extensions of group sequential trials for clinical investigations","volume":"103","author":"Liu","year":"2008","journal-title":"J Am Stat Assoc"},{"key":"2024032601023743500_bb0185","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/clpt.2010.215","article-title":"Dapoxetine for premature ejaculation","volume":"89","author":"Feige","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"2024032601023743500_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CE.S13841","article-title":"Dapoxetine: An evidence-based review of its effectiveness in treatment of premature ejaculation","volume":"7","author":"McCarty","year":"2012","journal-title":"Core Evid"},{"key":"2024032601023743500_bb0195","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/wnf.0b013e31815766f9","article-title":"Dapoxetine in the treatment of premature ejaculation","volume":"30","author":"McMahon","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"2024032601023743500_bb0200","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1111\/j.1743-6109.2010.01820.x","article-title":"Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: Integrated analyses of two phase 3 dapoxetine trials","volume":"7","author":"Porst","year":"2010","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515304847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515304847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/10\/9\/2312\/48192455\/jsm_10_9_2312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/10\/9\/2312\/48192455\/jsm_10_9_2312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T21:51:52Z","timestamp":1711403512000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/10\/9\/2312\/6940042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,1]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,9,1]]},"published-print":{"date-parts":[[2013,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jsm.12236","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718029908.793482008","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718029908.793482897","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718029908.793483164","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718029908.793482287","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718029908.793483002","asserted-by":"object"}]},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,9]]},"published":{"date-parts":[[2013,9,1]]}}}